Telesis Bio Inc. (TBIO) is a Biotechnology: Laboratory Analytical Instruments company listed on NASDAQ. There were no new wire items for TBIO in the last 30 days. The most recent was published May 28, 2025.

Translate Bio, Inc., a clinical-stage messenger RNA (mRNA) therapeutics company, develops medicines to treat diseases caused by protein or gene dysfunction. The company is developing MRT5005, which is in Phase I/II clinical trial for the treatment of cystic fibrosis. It is also developing MRT5500 for the treatment of SARS-CoV-2. The company was formerly known as RaNA Therapeutics, Inc. and changed its name to Translate Bio, Inc. in June 2017. Translate Bio, Inc. has a collaboration and license agreement with Sanofi Pasteur Inc. The company was founded in 2011 and is headquartered in Lexington, Massachusetts.

Latest news

25 items

TBIO FAQ

8 questions
  • What does Telesis Bio Inc. do?
    Translate Bio, Inc., a clinical-stage messenger RNA (mRNA) therapeutics company, develops medicines to treat diseases caused by protein or gene dysfunction. The company is developing MRT5005, which is in Phase I/II clinical trial for the treatment of cystic fibrosis. It is also developing MRT5500 for the treatment of SARS-CoV-2. The company was formerly known as RaNA Therapeutics, Inc. and changed its name to Translate Bio, Inc. in June 2017. Translate Bio, Inc. has a collaboration and license agreement with Sanofi Pasteur Inc. The company was founded in 2011 and is headquartered in...
  • What is the latest news on TBIO?
    Quantisnow has not tracked any new filings, ratings or press releases for TBIO in the last 30 days. The most recent wire item was published on May 28, 2025.
  • Where does TBIO stock trade?
    Telesis Bio Inc. (TBIO) is listed on NASDAQ.
  • What sector and industry is TBIO in?
    Telesis Bio Inc. operates in the Health Care sector, Biotechnology: Laboratory Analytical Instruments industry.
  • When did Telesis Bio Inc. go public?
    Telesis Bio Inc. (TBIO) completed its IPO in 2021.
  • What are analysts saying about TBIO?
    Across the last 4 analyst actions on Telesis Bio Inc., there were 0 upgrades and 1 downgrade. The most recent action was from Roth Capital: Neutral with a $38.00 price target on 2021-08-04. Recent price targets range from $38.00 to $45.00.
  • What companies are similar to TBIO?
    Notable peers in the same industry include A (Agilent Technologies Inc.), TXG (10x Genomics Inc.), BRKR (Bruker Corporation), RVTY (Revvity Inc.), WAT (Waters Corporation). Compare TBIO side-by-side with any of them on Quantisnow.
  • How can I track TBIO on Quantisnow?
    Quantisnow aggregates Telesis Bio Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow TBIO to receive live email and push alerts on every new disclosure.

Is something on this page wrong, or out of date? Request a change